Page 261 - 2021_02-Haematologica-web

Letters to the Editor
A
B
C
D
Figure 1. 5-fluorotroxacitabine (5FTRX) reduces cell growth and viability in hematologic cell lines and primary acute myeloid leukemia (AML) samples. (A) The structure of 5FTRX and its bio-activation by phosphorylation to the monophosphate (MP), diphosphate (DP), and triphosphate (TP). The enzymes known to catal- yse these phosphorylation reactions are indicated. DCK: deoxycytidine kinase; CMPK: cytidine monophosphate (CMP) kinase; PGK: phosphoglycerate kinase. (B) Hematologic cell lines were treated with increasing concentrations of 5FTRX for 96 hours (h). After incubation, cell growth and viability were measured by Cell Titer-Glo assay. Black bars indicate the myeloid cell lines; gray bars represent lymphoid cell lines. Data represent IC50, mean±standard deviation (SD). (C) Primary AML cells were treated with increasing concentrations of 5FTRX for 24 h and then plated into clonogenic growth assays. Data represent the number of colonies: mean±SD. (D) Peripheral blood stem cell (PBSC) were treated with increasing concentrations of 5FTRX or control for 24 h and then plated into clono- genic growth assays. Data represent the number of colonies: mean±SD. For all experiments, P-value was calculated using Student’s t-test; P<0.05 was consid- ered significant.
haematologica | 2021; 106(2)
575